Literature DB >> 2795463

Incorporation of amphotericin B (AMB) into liposomes alters AMB-induced acute nephrotoxicity in rabbits.

V Joly1, F Dromer, J Barge, P Yeni, N Seta, G Molas, C Carbon.   

Abstract

To investigate the protective effect of liposomes on acute amphotericin B (AMB) renal toxicity, we compared in rabbits the acute toxicity of 4 mg/kg of free-AMB and 4 or 10 mg/kg of liposomal AMB (L-AMB) during 90 min after antibiotic infusion. Free-AMB exhibited immediate nephrotoxicity with a 44% decrease of the glomerular filtration rate and alteration of tubular cell membrane permeability expressed as increases in urinary pH (6.5 vs. 4.7), potassium fractional excretion (95% vs. 30%) and sodium fractional excretion (26% vs. 4%). Urinary excretion of the lysosomal enzyme N-acetylglucosaminidase was unchanged by free-AMB. Incorporation of AMB into liposomes prevented the toxic effects of free-AMB on glomerular filtration and tubular cells membrane, but significantly increased N-acetylglucosaminidase urinary excretion (380 and 180% in animals receiving 4 and 10 mg/kg of L-AMB, respectively). Absolute AMB urinary excretion during the experiment was unchanged by liposomes and was always less than 1% of the total dose administered. Liposomes alone exhibited no toxicity. These results suggest that liposomes could increase the interaction between AMB and lysosomes leading to an additional mechanism of cellular injury. They admonish close monitoring of renal function and enzymuria in clinical situations in which L-AMB is being used.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2795463

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

Review 1.  In vitro models for studying toxicity of antifungal agents.

Authors:  V Joly; J Bolard; P Yeni
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

2.  Improvement of amphotericin B activity during experimental cryptococcosis by incorporation into specific immunoliposomes.

Authors:  F Dromer; J Barbet; J Bolard; J Charreire; P Yeni
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

3.  Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats.

Authors:  G W Boswell; I Bekersky; D Buell; R Hiles; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

4.  Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies.

Authors:  A Adedoyin; J F Bernardo; C E Swenson; L E Bolsack; G Horwith; S DeWit; E Kelly; J Klasterksy; J P Sculier; D DeValeriola; E Anaissie; G Lopez-Berestein; A Llanos-Cuentas; A Boyle; R A Branch
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

5.  Influence of phospholipid/amphotericin B ratio and phospholipid type on in vitro renal cell toxicities and fungicidal activities of lipid-associated amphotericin B formulations.

Authors:  V Joly; J Bolard; L Saint-Julien; C Carbon; P Yeni
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

6.  Limited protection by small unilamellar liposomes against the renal tubular toxicity induced by repeated amphotericin B infusions in rats.

Authors:  P Longuet; V Joly; P Amirault; N Seta; C Carbon; P Yeni
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

7.  Comparison of nephrotoxicities of different polyoxyethyleneglycol formulations of amphotericin B in rats.

Authors:  C Tasset; V Preat; A Bernard; M Roland
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

Review 8.  Sodium chloride treatment of amphotericin B nephrotoxicity. Standard of care?

Authors:  C M Anderson
Journal:  West J Med       Date:  1995-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.